Novoic is an AI-first, digital biotechnology company, founded by researchers from Oxford and Cambridge University. The company is developing, testing, and validating a new class of algorithms for analysing audio-linguistic patterns of speech that are predictive of the earliest stages of neurological diseases, such as Alzheimer's and Parkinson's disease–where these patterns have been found to change decades before traditional diagnosis. The team is working to put the first clinically viable speech-based algorithms on the market, as software-as-medical-device. The company has active clinical programmes in a number of neurodegenerative and psychiatric conditions.